ATE396191T1 - Azaindolylalkylaminderivate als 5- hydroxytryptamin-6-liganden - Google Patents

Azaindolylalkylaminderivate als 5- hydroxytryptamin-6-liganden

Info

Publication number
ATE396191T1
ATE396191T1 AT02795890T AT02795890T ATE396191T1 AT E396191 T1 ATE396191 T1 AT E396191T1 AT 02795890 T AT02795890 T AT 02795890T AT 02795890 T AT02795890 T AT 02795890T AT E396191 T1 ATE396191 T1 AT E396191T1
Authority
AT
Austria
Prior art keywords
hydroxytryptamine
ligands
azaindolylalkylamine
derivatives
azaindolylalkylamine derivatives
Prior art date
Application number
AT02795890T
Other languages
English (en)
Inventor
Ronald Bernotas
Derek Cole
William Lennox
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE396191T1 publication Critical patent/ATE396191T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT02795890T 2001-12-20 2002-12-17 Azaindolylalkylaminderivate als 5- hydroxytryptamin-6-liganden ATE396191T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34283801P 2001-12-20 2001-12-20

Publications (1)

Publication Number Publication Date
ATE396191T1 true ATE396191T1 (de) 2008-06-15

Family

ID=23343489

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02795890T ATE396191T1 (de) 2001-12-20 2002-12-17 Azaindolylalkylaminderivate als 5- hydroxytryptamin-6-liganden

Country Status (22)

Country Link
US (3) US6800640B2 (de)
EP (1) EP1456206B1 (de)
JP (1) JP4339123B2 (de)
KR (1) KR20040077861A (de)
CN (1) CN1620455A (de)
AR (1) AR037907A1 (de)
AT (1) ATE396191T1 (de)
AU (1) AU2002360618B2 (de)
BR (1) BR0215151A (de)
CA (1) CA2470832C (de)
CO (1) CO5590960A2 (de)
DE (1) DE60226775D1 (de)
DK (1) DK1456206T3 (de)
ES (1) ES2305338T3 (de)
IL (1) IL162242A0 (de)
MX (1) MXPA04005886A (de)
NO (1) NO20043099L (de)
PL (1) PL370890A1 (de)
RU (1) RU2004122094A (de)
TW (1) TW200301251A (de)
WO (1) WO2003053970A1 (de)
ZA (1) ZA200405733B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2222828B1 (es) 2003-07-30 2006-04-16 Laboratorios Del Dr. Esteve, S.A. Derivados de 1-sulfonilindoles, su preparacion y su aplicacion como medicamentos.
WO2005056547A2 (en) 2003-12-04 2005-06-23 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases
ATE412651T1 (de) 2004-06-09 2008-11-15 Glaxo Group Ltd Pyrrolopyridinderivate
KR100958829B1 (ko) * 2004-09-03 2010-05-25 주식회사유한양행 피롤로[2,3-ｃ]피리딘 유도체 및 그의 제조방법
US7541366B2 (en) 2004-09-03 2009-06-02 Yuhan Corporation Pyrrolo[3,2-c]pyridine derivatives and processes for the preparation thereof
KR101142363B1 (ko) 2005-06-27 2012-05-21 주식회사유한양행 피롤로피리딘 유도체를 포함하는 항암제 조성물
EP1947085A1 (de) * 2007-01-19 2008-07-23 Laboratorios del Dr. Esteve S.A. Substituierte Indolsulfonamidverbindungen, ihre Herstellung und ihre Verwendung als Medikamente
AU2008254588B2 (en) * 2007-05-21 2013-01-17 Sgx Pharmaceuticals, Inc. Heterocyclic kinase modulators
CA2687132A1 (en) * 2007-05-24 2008-12-04 Memory Pharmaceuticals Corporation 4' substituted compounds having 5-ht6 receptor affinity
US20100016297A1 (en) * 2008-06-24 2010-01-21 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
US20100022581A1 (en) * 2008-07-02 2010-01-28 Memory Pharmaceuticals Corporation Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity
US20100029629A1 (en) * 2008-07-25 2010-02-04 Memory Pharmaceuticals Corporation Acyclic compounds having 5-ht6 receptor affinity
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
US20100056531A1 (en) * 2008-08-22 2010-03-04 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
US8592448B2 (en) * 2008-11-20 2013-11-26 OSI Pharmaceuticals, LLC Substituted pyrrolo[2,3-b]-pyridines and -pyrazines
US8119683B2 (en) * 2009-08-10 2012-02-21 Taipei Medical University Aryl substituted sulfonamide compounds and their use as anticancer agents
WO2011143646A1 (en) 2010-05-14 2011-11-17 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
WO2012160464A1 (en) * 2011-05-26 2012-11-29 Daiichi Sankyo Company, Limited Heterocyclic compounds as protein kinase inhibitors
EP2734186B1 (de) 2011-07-22 2018-09-12 GlaxoSmithKline LLC Zusammensetzung
CA2880576A1 (en) 2012-08-24 2014-02-27 Glaxosmithkline Llc Pyrazolopyrimidine compounds
CA2890198A1 (en) 2012-11-20 2014-05-30 Diane Mary Coe Novel compounds
RU2643371C2 (ru) 2012-11-20 2018-02-01 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Новые соединения
NZ707319A (en) 2012-11-20 2019-09-27 Glaxosmithkline Llc 5h-pyrrolo[3,2-d]pyrimidin-4-amine compounds and their use in the treatment of allergic diseases and other inflammatory conditions
CN102977094A (zh) * 2012-11-30 2013-03-20 盛世泰科生物医药技术(苏州)有限公司 一种2-羟基-1,5-萘啶的合成方法
EP3083588B1 (de) 2013-12-20 2020-12-09 Sunshine Lake Pharma Co., Ltd. Aromatische heterocyclische verbindungen und deren anwendung in pharmazeutika
JP6515175B2 (ja) 2014-07-08 2019-05-15 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 芳香族ヘテロ環誘導体及びその医薬的適用
RU2725886C1 (ru) 2017-03-30 2020-07-07 ЭксДабл-Ю ЛЭБОРЕТРИЗ ИНК. Бициклические гетероарильные производные и их получение и применение
IL311211A (en) 2021-09-03 2024-05-01 Alexander Shulgin Res Institute Inc Asymmetric allyl tryptamines

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977131A (en) 1997-04-09 1999-11-02 Pfizer Inc. Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents
US6100291A (en) * 1998-03-16 2000-08-08 Allelix Biopharmaceuticals Inc. Pyrrolidine-indole compounds having 5-HT6 affinity
GB9820113D0 (en) * 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
CA2370147C (en) * 1999-04-21 2009-07-28 Allelix Biopharmaceuticals Inc. Piperidine-indole compounds having 5-ht6 affinity
AU779832B2 (en) * 1999-08-12 2005-02-10 Nps Pharmaceuticals, Inc. Azaindoles having serotonin receptor affinity
US6476034B2 (en) 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
IL162243A0 (en) * 2001-12-20 2005-11-20 Wyeth Corp Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
JP2008523146A (ja) * 2004-12-14 2008-07-03 ワイス 神経変性障害の処置および予防のための５−ｈｔ６アゴニストの使用

Also Published As

Publication number Publication date
CN1620455A (zh) 2005-05-25
JP4339123B2 (ja) 2009-10-07
IL162242A0 (en) 2005-11-20
DK1456206T3 (da) 2008-09-08
CA2470832C (en) 2010-09-21
PL370890A1 (en) 2005-05-30
EP1456206A1 (de) 2004-09-15
US20050020598A1 (en) 2005-01-27
US20030171395A1 (en) 2003-09-11
WO2003053970A1 (en) 2003-07-03
US7585876B2 (en) 2009-09-08
US7297705B2 (en) 2007-11-20
US20080114023A1 (en) 2008-05-15
AU2002360618B2 (en) 2009-01-08
ES2305338T3 (es) 2008-11-01
BR0215151A (pt) 2004-10-19
MXPA04005886A (es) 2004-09-13
CA2470832A1 (en) 2003-07-03
NO20043099L (no) 2004-08-17
RU2004122094A (ru) 2005-03-27
US6800640B2 (en) 2004-10-05
AU2002360618A1 (en) 2003-07-09
TW200301251A (en) 2003-07-01
CO5590960A2 (es) 2005-12-30
EP1456206B1 (de) 2008-05-21
AR037907A1 (es) 2004-12-22
DE60226775D1 (de) 2008-07-03
ZA200405733B (en) 2005-10-19
JP2005519046A (ja) 2005-06-30
KR20040077861A (ko) 2004-09-07

Similar Documents

Publication Publication Date Title
ATE396191T1 (de) Azaindolylalkylaminderivate als 5- hydroxytryptamin-6-liganden
DE60207815D1 (de) 1-aryl-oder 1-alkylsulfonylbenzazol derivate als 5-hydroxytryptamin-6 liganden
ATE335477T1 (de) Indolylalkylamin-derivate als 5-hydroxytryptamin- 6 liganden
ATE368658T1 (de) Hetorocyclindazole und -azaindazole verbindungen als 5-hydroxytryptamine-6 liganden
ATE355289T1 (de) 1-(aminoalkyl)-3-sulfonylazaindole als 5- hydroxytryptamin-6 liganden
ATE319451T1 (de) Tetrahydrochinolin-derivate
ATE327232T1 (de) Heterozyklylalkylindole oder -azaindole als 5- hydroxytryptamine-6 liganden
ATE312827T1 (de) 3-substituierte-4-pyrimidonderivate
NO20034168L (no) Koagulasjonsfaktor VII-derivater
IL158445A0 (en) Heterocyclyloxy-, -thioxy-and-aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
DE50202178D1 (de) Neue sulfonat-substituierte pyrazolopyridinderivate
EE200300447A (et) Asendatud bensofuraan-2-karboksamiidide derivaadid
IL158448A0 (en) Heterocyclylalkoxy- alkylthio-and-alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
DE60223031D1 (de) Arylpiperazin gebundene tetrahydroindolonderivate
DE60201463D1 (de) Indanon-Derivate als Duftstoffe
ATE382601T1 (de) Substituierte 4-aminocyclohexanolderivate
DE60202381D1 (de) Paroxetin-n-formyl-derivate
ITMI20011758A0 (it) Ligandi

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties